• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Echo Therapeutics readies Prelude SkinPrep for clinical trials

January 11, 2010 By drugdelivery

Echo Therapeutics Inc. (OTC:ECTE) reached a milestone with one of its two flagship products, the Prelude SkinPrep system, which is ready for clinical trials examining its use in dispensing lidocaine.

The Franklin, Mass.-based company, which is also developing a needle-free glucose monitoring system called the Symphony tCGM, said its development work on the Prelude system is complete and it’s ready for a study in the “near term.”

That study, to be conducted in conjunction with Ferndale Pharma Group, is aimed at driving an application for 510(k) clearance from the Food & Drug Administration. If the system wins clearance for dispensing lidocaine, it will give Echo access to what it called the more than $1 billion market for “enhanced, fast acting topical lidocaine.”

Echo said it also expects to test the Prelude for use with the Symphony system, which is undergoing a clinical trial expected to conclude during the fourth quarter. Preliminary results from the trial, examining the glucose monitor’s effectiveness compared with what Echo calls the industry’s “gold standard,” showed an accuracy rate of 97 percent.

The company is also on the investment trail, having engaged the services of Hayden IR, a New York-based investor relations consulting firm, to manage a “strategic investor relations campaign” this year. Echo’s banked more than $3.5 million in recent months, raising half a million from Philadelphia-area investors early in December, 2009, and another $3 million in November from a private stock placement.

Filed Under: Business/Financial News, Clinical Trials, Diagnostics, Drug-Device Combinations Tagged With: Echo Therapeutics Inc.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS